Gene therapy company Skyline Therapeutics has secured an orphan drug designation from the US Food and Drug Administration ...

Boehringer Ingelheim and CDR-Life have reported positive outcomes from the Phase I clinical trial of BI 771716, a new ...

Durga Borkar, MD, sat down with Sydney Crago of Modern Retina to discuss one of her presentations on the first time phase 2 ...

Amgen’s Pavblu (aflibercept-ayyh) is the fifth biosimilar referencing Eylea (aflibercept) to be approved for American ...

EyeBio’s main asset is Restoret, an intravitreally delivered trispecific antibody that acts as an agonist of the Wnt signalling pathway and is in the phase 1b/2a AMARONE study in DME and ...

“There are two advanced forms of AMD: the wet form or neovascular form, [for which] there are treatments, there are medicines we inject intravitreally in patients routinely, and we’ve been ...

*Syndromes include WNF, West Nile meningitis, West Nile encephalitis and WNP. ‡ Overall, WNND represents 1% of human WNV infections. § WNP may occur in the context of any other manifestation of ...

Using BaseScope, the team showed that intravitreally delivered ADVM-062 can transduce and express human L-opsin in foveal cone cells. They could also quantify the number of cells expressing the ...

Nanomedicine. 2009;4(6):599-604. This editorial aims to demonstrate that the eye is an excellent organ to consider for nanomedicine. It discusses two major causes of blindness and describes ocular ...

Skyline Therapeutics (Shanghai) Co. Ltd.’s SKG-1108, a novel one-time intravitreally delivered gene therapy, has been awarded U.S. orphan drug designation for the treatment of retinitis pigmentosa.

The trial assessed the tolerability, safety, and pharmacokinetics of varying doses of BI 771716 administered intravitreally to patients aged 50 years and above. It aimed to evaluate the tolerance ...